Fenwick Represents Synthego in the Sale of Engineered Cell Solutions Business to EditCo Bio

Fenwick is representing Synthego, a provider of genome engineering solutions, in its sale of its engineered cell solutions and enhanced guide RNA business to EditCo Bio, a developer of cells as reagents.

The acquisition of Synthego’s engineered cell solutions and enhanced guide RNA business, launches EditCo Bio as a company. EditCo Bio was born from Synthego’s cell engineering expertise and is uniquely positioned to deliver edited cells and highly optimized guide RNA designs for the rapidly expanding CRISPR market. EditCo Bio will be led by former Synthego President and Chief Operating Officer, John Tan, and operate as an independent business with financing and support from life sciences investment firm Telegraph Hill Partners. More information can be obtained from Synthego’s announcement.

The Fenwick transaction team includes corporate partners Ethan Skerry and Steven Levine, counsel Brian Hicks and associates Zachary Portnoy, Jiarui Li, David Heckman, Zoe Zhang and Brandon Ho; technology transactions partner Stefano Quintini, associates Pinar Bailey, Trevor Snider and Ju Yun (Julie) Son; executive compensation and employee benefits partner Matt Cantor and associate Jonathan Stepheson; and tax partner Mike Knobler and associate Kris Hatch.